Barber Financial Group Inc. bought a new stake in Pfizer (NYSE:PFE) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 5,661 shares of the biopharmaceutical company’s stock, valued at approximately $205,000.
Several other hedge funds have also modified their holdings of PFE. Americafirst Capital Management LLC acquired a new stake in shares of Pfizer during the 3rd quarter valued at $127,000. Delphi Private Advisors LLC lifted its holdings in Pfizer by 84.3% during the 4th quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,600 shares during the period. Lipe & Dalton lifted its holdings in Pfizer by 6.9% during the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 300 shares during the period. Legacy Advisors LLC acquired a new position in Pfizer during the 3rd quarter worth about $164,000. Finally, Oak Point Wealth Management acquired a new position in Pfizer during the 4th quarter worth about $165,000. 71.19% of the stock is currently owned by hedge funds and other institutional investors.
In related news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the completion of the sale, the insider now directly owns 36,959 shares of the company’s stock, valued at approximately $1,374,505.21. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sally Susman sold 33,368 shares of the business’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $37.03, for a total value of $1,235,617.04. Following the completion of the sale, the executive vice president now directly owns 191,505 shares of the company’s stock, valued at $7,091,430.15. The disclosure for this sale can be found here. Insiders sold a total of 248,037 shares of company stock valued at $9,064,785 over the last ninety days. 0.06% of the stock is currently owned by corporate insiders.
Several brokerages have commented on PFE. Citigroup reaffirmed a “sell” rating on shares of Pfizer in a report on Thursday, April 12th. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Thursday, April 12th. Berenberg Bank reaffirmed a “neutral” rating and set a $37.00 target price on shares of Pfizer in a report on Wednesday, April 11th. Jefferies Group set a $38.00 target price on Pfizer and gave the stock a “hold” rating in a report on Friday, April 13th. Finally, UBS set a $42.00 target price on Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $39.20.
PFE stock opened at $36.53 on Friday. Pfizer has a 1-year low of $31.67 and a 1-year high of $39.43. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10. The stock has a market capitalization of $216,267.59, a PE ratio of 13.78, a price-to-earnings-growth ratio of 1.82 and a beta of 0.90.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. During the same period last year, the company posted $0.47 EPS. The business’s quarterly revenue was up .6% on a year-over-year basis. analysts expect that Pfizer will post 2.95 earnings per share for the current year.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.